drugset / Trial / NCT02966548
Safety Study of BMS-986016 With or Without Nivolumab in Patients With Advanced Solid Tumors
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study will be used to determine the safety and tolerability of BMS-986016 administered alone and in combination with Nivolumab in subjects with advanced solid tumors.
Timeline
- Start
- 2017-01-04
- Primary completion
- 2024-07-09
- Completion
- 2024-07-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nivolumab | Monoclonal antibody | — | Intravenous |
| Subject | Relatlimab | Monoclonal antibody | — | Intravenous |